RPG Life Sciences Limited (RPGLIFE.BO)
INR 2228.1
(1.76%)
INR 2228.1
(1.76%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | -30.3 Million INR | -0.33% |
| 2022 | -30.2 Million INR | -1106.67% |
| 2021 | 3 Million INR | -59.46% |
| 2020 | 7.4 Million INR | -51.32% |
| 2019 | 15.2 Million INR | -76.9% |
| 2018 | 65.8 Million INR | -35.68% |
| 2017 | 102.3 Million INR | -36.26% |
| 2016 | 160.5 Million INR | 6320.0% |
| 2015 | 2.5 Million INR | -21.88% |
| 2014 | 3.2 Million INR | -11.11% |
| 2013 | 3.6 Million INR | -96.58% |
| 2012 | 105.2 Million INR | -49.1% |
| 2011 | 206.7 Million INR | -16.65% |
| 2010 | 248 Million INR | -49.44% |
| 2009 | 490.52 Million INR | -13.01% |
| 2008 | 563.91 Million INR | -22.52% |
| 2007 | 727.77 Million INR | -14.26% |
| 2006 | 848.82 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2023 Q4 | - INR | 0.0% |
| 2023 FY | - INR | 100.0% |
| 2023 Q2 | - INR | 0.0% |
| 2023 Q3 | - INR | 0.0% |
| 2023 Q1 | - INR | 100.0% |
| 2022 Q2 | - INR | 0.0% |
| 2022 Q4 | -30.2 Million INR | 0.0% |
| 2022 Q3 | - INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | -30.2 Million INR | -1106.67% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 3 Million INR | -59.46% |
| 2021 Q4 | 3 Million INR | 0.0% |
| 2021 Q2 | 5.1 Million INR | 0.0% |
| 2020 Q4 | 7.4 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 11.1 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 7.4 Million INR | -51.32% |
| 2019 FY | 15.2 Million INR | -76.9% |
| 2019 Q4 | 15.2 Million INR | 0.0% |
| 2019 Q2 | 33.3 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q2 | 73.1 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 65.8 Million INR | -35.68% |
| 2018 Q4 | 65.8 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 FY | 102.3 Million INR | -36.26% |
| 2017 Q4 | 102.3 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 131.4 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q2 | 2.4 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 160.5 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 160.5 Million INR | 6320.0% |
| 2015 Q4 | 2.5 Million INR | 0.0% |
| 2015 Q2 | 3.2 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 2.5 Million INR | -21.88% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 3.2 Million INR | -11.11% |
| 2014 Q4 | 3.2 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.9 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 3.6 Million INR | 0.0% |
| 2013 FY | 3.6 Million INR | -96.58% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.3 Million INR | 0.0% |
| 2012 Q4 | 105.2 Million INR | 0.0% |
| 2012 FY | 105.2 Million INR | -49.1% |
| 2012 Q2 | 237.6 Million INR | 0.0% |
| 2011 FY | 206.7 Million INR | -16.65% |
| 2010 FY | 248 Million INR | -49.44% |
| 2009 FY | 490.52 Million INR | -13.01% |
| 2008 FY | 563.91 Million INR | -22.52% |
| 2007 FY | 727.77 Million INR | -14.26% |
| 2006 FY | 848.82 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 235.2 Million INR | 112.883% |
| Amrutanjan Health Care Limited | 13.96 Million INR | 316.924% |
| Sigachi Industries Limited | 265.79 Million INR | 111.4% |
| Bal Pharma Limited | 363.82 Million INR | 108.328% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 127.144% |
| Medico Remedies Limited | 8.67 Million INR | 449.4% |
| Lasa Supergenerics Limited | - INR | Infinity% |
| Venus Remedies Limited | 386.8 Million INR | 107.834% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 128.424% |
| Alpa Laboratories Limited | - INR | Infinity% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 102.16% |
| Shilpa Medicare Limited | 5.6 Billion INR | 100.541% |
| Aarti Drugs Limited | 2.75 Billion INR | 101.1% |
| Lupin Limited | 1.55 Billion INR | 101.951% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 100.142% |
| Zydus Lifesciences Limited | 251 Million INR | 112.072% |
| Windlas Biotech Limited | 20.18 Million INR | 250.149% |
| Suven Life Sciences Limited | - INR | Infinity% |
| Eris Lifesciences Limited | 6.54 Billion INR | 100.463% |
| Valiant Laboratories Limited | 746.63 Million INR | 104.058% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 112.817% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 102.863% |
| Ipca Laboratories Limited | 5.8 Billion INR | 100.522% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 108.513% |
| Achyut Healthcare Limited | - INR | Infinity% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | 327.82% |
| Bajaj HealthCare Limited | 650.34 Million INR | 104.659% |
| Mankind Pharma Limited | 248.67 Million INR | 112.184% |
| Laurus Labs Limited | 8.6 Billion INR | 100.352% |
| Piramal Pharma Limited | 24.83 Billion INR | 100.122% |
| Syncom Formulations (India) Limited | -1.21 Million INR | -2385.644% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 100.189% |
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 104.819% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 101.997% |
| Unichem Laboratories Limited | 382.22 Million INR | 107.927% |
| Sequent Scientific Limited | 1.42 Billion INR | 102.123% |
| Novartis India Limited | 50.7 Million INR | 159.763% |
| Wanbury Limited | 820 Million INR | 103.695% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 114.268% |
| Wockhardt Limited | 8.91 Billion INR | 100.34% |
| Themis Medicare Limited | 267.74 Million INR | 111.317% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 140.095% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 100.096% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 120.527% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 100.506% |
| Divi's Laboratories Limited | 20 Million INR | 251.5% |
| NATCO Pharma Limited | 53 Million INR | 157.17% |
| Gufic Biosciences Limited | 1.53 Billion INR | 101.968% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 100.3% |
| Procter & Gamble Health Limited | 68.8 Million INR | 144.041% |
| FDC Limited | 2.46 Million INR | 1328.71% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 101.651% |
| Granules India Limited | 689.71 Million INR | 104.393% |
| Medicamen Biotech Limited | 12.55 Million INR | 341.338% |
| Alkem Laboratories Limited | 400 Million INR | 107.575% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | 208.852% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | 949.93% |
| Megasoft Limited | 1.35 Billion INR | 102.233% |
| ZIM Laboratories Limited | 356 Million INR | 108.511% |
| Strides Pharma Science Limited | 6.71 Billion INR | 100.451% |
| Neuland Laboratories Limited | 449.2 Million INR | 106.745% |
| Morepen Laboratories Limited | 33.64 Million INR | 190.071% |
| Hikal Limited | 4.22 Billion INR | 100.717% |
| Indoco Remedies Limited | 3.51 Billion INR | 100.861% |
| Aarti Pharmalabs Limited | 400 Thousand INR | 7675.0% |
| Kilitch Drugs (India) Limited | - INR | Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 122.69% |
| Hester Biosciences Limited | 1.81 Billion INR | 101.667% |